THOUSAND OAKS, Calif.
Dec. 5, 2012
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from several studies at the 54th Annual Meeting of the American Society of Hematology (ASH) from
Dec. 8-11, 2012
. These include updated results from a Phase 2 trial evaluating blinatumomab in B-precursor acute lymphoblastic leukemia (ALL) and data evaluating long-term use of Nplate
(romiplostim) in pediatric chronic immune thrombocytopenia (ITP).
"The research we are presenting at this year's annual meeting of the American Society of Hematology reflects Amgen's ongoing commitment to develop medicines for patients with the greatest need for treatment options," said
Sean E. Harper
, M.D., executive vice president of Research and Development at Amgen. "Our data show exciting progress in fighting hematologic diseases, particularly in orphan diseases like ALL and ITP."
ABSTRACTS OF INTEREST INCLUDE:
Abstracts are currently available on the ASH website at
. Updated data will be presented at the meeting.
Blinatumomab (AMG 103) in B-precursor Acute Lymphoblastic Leukemia (ALL)
Nplate in ITP
- Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate and Prolongs Overall Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL): Results from a Phase 2 Single-arm Dose-ranging TrialLead Author: Max S. Topp, Department of Internal Medicine II, Division of Hematology and Medical Oncology, Wuerzburg University Medical Center, Wuerzburg, GermanyAbstract No. 670Oral Presentation: Monday, Dec. 10, 4:30 p.m. – 6:00 p.m. EST, A103, Level 1, Building A
- Long-Term Use of Open-Label Romiplostim in Children with Chronic/Refractory Immune Thrombocytopenia (ITP): Results from an Open-label Phase 1/2 Randomized Double-blind Placebo-controlled Study. Lead Author: James B. Bussel, Department of Pediatrics, Division of Hematology, Weill Medical College of Cornell University, New York, NYAbstract No. 621Oral Presentation: Monday, Dec. 10, 4:30 p.m. – 6:00 p.m. EST, Georgia Ballroom 3, Level 3, Building C
- Integrated Analysis of Long Term Safety in Patients (pts) with Chronic Immune Thrombocytopenia (ITP) Treated with Romiplostim: Results from a Safety Analysis of Pooled Data from ITP Romiplostim Clinical StudiesLead Author: Douglas B. Cines, Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PAAbstract No. 2185Poster Presentation: Sunday, Dec. 9, 6:00 p.m. – 8:00 p.m. EST, Hall B1-B2, Level 1, Building B
- A Systematic Literature Review and Meta-Analysis of the Risk of Thromboembolic Events in Patients with Immune Thrombocytopenia (ITP) in Observational Studies: Results from a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Thrombopoietin-receptor Agonists (TPOr)Lead Author: Wendy Langeberg, Amgen, Thousand Oaks, CAAbstract No. 2187Poster Presentation: Sunday, Dec. 9, 6:00 p.m. – 8:00 p.m. EST, Hall B1-B2, Level 1, Building B
Nplate in Myelodysplastic Syndromes (MDS)
- Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice – Interim Results From a Large, European, Observational Study Lead Author: Dominik Selleslag, Department of Hematology, AZ St-Jan, Brugge, BelgiumAbstract No. 3316Poster Presentation: Monday, Dec. 10, 6:00 p.m. – 8:00 p.m. EST, Hall B1-B2, Level 1, Building B
- Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study Lead Author: Hagop M. Kantarjian, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TXAbstract No. 421Oral Presentation: Monday, Dec. 10, 10:30 a.m. – 12:00 p.m. EST, B216-B217, Level 2, Building B
Febrile Neutropenia Data
- Development and Validation of a Model to Predict Response to Romiplostim in Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Results from a Placebo-controlled Study Lead Author: Mikkael A. Sekeres, Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OHAbstract No. 2801Poster Presentation: Sunday, Dec. 9, 6:00 p.m. – 8:00 p.m. EST, Hall B1-B2, Level 1, Building B
About Acute Lymphoblastic Leukemia (ALL)
- Clinical and Economic Burden During Hospitalizations Among Cancer Patients with Febrile Neutropenia: Evidence From U.S. Hospitals, 2007-2010Lead Author: Brian Dulisse, Premier Healthcare Alliance, Charlotte, NCAbstract No. 239Oral Presentation: Sunday, Dec. 9, 4:30 p.m. – 6:00 p.m. EST, C211-C213, Level 2, Building C
Acute lymphoblastic leukemia (ALL) is an aggressive cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are made. The disease progresses rapidly and affects immature blood cells, rather than mature ones.
Worldwide, ALL accounts for more than 12 percent of leukemia. Of the 42,000 people diagnosed worldwide, 31,000 will die from the disease.
Patients with ALL have abnormal white blood cells (lymphocytes) that crowd out healthy white blood cells, red blood cells and platelets, and can lead to serious side effects such as infection, anemia (fatigue), and easy bleeding.
About Blinatumomab (AMG 103)
Blinatumomab (AMG 103) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) and is currently being investigated for the treatment of ALL and non-Hodgkin's lymphoma. Blinatumomab is a bispecific T cell engager (BiTE
) antibody. BiTE antibodies are designed to engage two different targets simultaneously. This dual binding ability allows BiTE antibodies to act as bridges between T cells (a type of white blood cell capable of killing other cells perceived as threats) and tumor cells. BiTE antibodies place the T cells within reach to inject toxins into the tumor cell, triggering the cell to die through apoptosis. Blinatumomab is designed to direct the T cells to target cells expressing CD19, a protein found on the surface of most B cell derived leukemias and lymphomas.
About Immune Thrombocytopenia (ITP)
In patients with immune thrombocytopenia (ITP), platelets – blood elements needed to prevent bleeding – are destroyed by the patient's own immune system. Low platelet counts leave ITP patients open to sudden serious bleeding events. The risk for serious bleeding events increases when platelet counts drop to less than 30,000 platelets per microliter; normal counts range from 150,000 to 400,000 platelets per microliter.
ITP has historically been considered a disease of platelet destruction although recent data suggest that the body's natural platelet production processes in ITP are also unable to compensate for low levels of platelets in the blood.
the United States
combined, ITP is estimated to affect 50 to 100 new persons per million annually, with half of the new cases diagnosed in children.
ITP affects about twice as many adult women as men.
About Nplate ® (romiplostim)
(romiplostim) is the first FDA-approved treatment specifically for adult chronic ITP. It is also being investigated for potential use in children ages 12 months to 18 years old with persistent severe thrombocytopenia.
In the U.S., Nplate is indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than chronic ITP. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts.